Crisafulli Ernesto, Barbeta Enric, Ielpo Antonella, Torres Antoni
1Department of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy.
2Pneumology Department, Clinic Institute of Thorax, Hospital Clinic of Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Multidiscip Respir Med. 2018 Oct 2;13:36. doi: 10.1186/s40248-018-0149-0. eCollection 2018.
Patients with chronic obstructive pulmonary disease (COPD) may experience an acute worsening of respiratory symptoms that results in additional therapy; this event is defined as a COPD exacerbation (AECOPD). Hospitalization for AECOPD is accompanied by a rapid decline in health status with a high risk of mortality or other negative outcomes such as need for endotracheal intubation or intensive care unit (ICU) admission. Treatments for AECOPD aim to minimize the negative impact of the current exacerbation and to prevent subsequent events, such as relapse or readmission to hospital.
In this narrative review, we update the scientific evidence about the in-hospital pharmacological and non-pharmacological treatments used in the management of a severe AECOPD. We review inhaled bronchodilators, steroids, and antibiotics for the pharmacological approach, and oxygen, high flow nasal cannulae (HFNC) oxygen therapy, non-invasive mechanical ventilation (NIMV) and pulmonary rehabilitation (PR) as non-pharmacological treatments. We also review some studies of non-conventional drugs that have been proposed for severe AECOPD.
Several treatments exist for severe AECOPD patients requiring hospitalization. Some treatments such as steroids and NIMV (in patients admitted with a hypercapnic acute respiratory failure and respiratory acidosis) are supported by strong evidence of their efficacy. HFNC oxygen therapy needs further prospective studies. Although antibiotics are preferred in ICU patients, there is a lack of evidence regarding the preferred drugs and optimal duration of treatment for non-ICU patients. Early rehabilitation, if associated with standard treatment of patients, is recommended due to its feasibility and safety. There are currently few promising new drugs or new applications of existing drugs.
慢性阻塞性肺疾病(COPD)患者可能会出现呼吸道症状急性加重,从而需要额外治疗;这一事件被定义为慢性阻塞性肺疾病急性加重(AECOPD)。AECOPD导致的住院伴随着健康状况的迅速恶化,具有较高的死亡风险或其他负面结果,如需要气管插管或入住重症监护病房(ICU)。AECOPD的治疗旨在将当前加重的负面影响降至最低,并预防后续事件,如复发或再次入院。
在这篇叙述性综述中,我们更新了关于重度AECOPD管理中使用的院内药物和非药物治疗的科学证据。我们回顾了用于药物治疗方法的吸入性支气管扩张剂、类固醇和抗生素,以及作为非药物治疗的氧气、高流量鼻导管(HFNC)氧疗、无创机械通气(NIMV)和肺康复(PR)。我们还回顾了一些针对重度AECOPD提出的非传统药物的研究。
对于需要住院治疗的重度AECOPD患者有多种治疗方法。一些治疗方法,如类固醇和NIMV(用于因高碳酸血症急性呼吸衰竭和呼吸性酸中毒入院的患者),有强有力的疗效证据支持。HFNC氧疗需要进一步的前瞻性研究。尽管抗生素在ICU患者中是首选,但对于非ICU患者,缺乏关于首选药物和最佳治疗持续时间的证据。由于其可行性和安全性,建议早期康复,如果与患者的标准治疗相结合。目前几乎没有有前景的新药或现有药物的新应用。